# A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome

> **NCT04900350** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Akeso** · enrollment: 136 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** AK117
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT04900350
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-18
- **Primary completion:** 2025-09
- **Final completion:** 2025-12
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04900350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04900350, "A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04900350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*